Endogenous Candida endophthalmitis after intravenous anesthesia with propofol

M. J. Daily, J. B. Dickey and K. H. Packo
Department of Ophthalmology, Loyola University Medical Center, Maywood, IL 60153.

Propofol is an intravenous anesthetic agent that was approved by the US Food and Drug Administration in October 1989. It has gained rapid acceptance and is in widespread use. In June 1990, the Centers for Disease Control reported four clusters of postsurgical infections associated with the use of propofol. We describe one of those clusters, consisting of four cases of endogenous Candida albicans endophthalmitis. These infections occurred in nonimmunocompromised patients after they had undergone nonophthalmologic surgery in which propofol had been used as anesthesia. An investigation by the Centers for Disease Control concluded that the infections in these patients were due to extrinsic contamination of propofol during preparation for use at the hospital. Ophthalmologists should be aware of this new potential source of endogenous endophthalmitis.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Routine handling of propofol prevents contamination as effectively as does strict adherence to the manufacturer's recommendations: [Le maniement d'usage du propofol previent la contamination aussi effectivement que la stricte adhesion aux recommandations du fabricant]
Lorenz et al.
Canadian J. Anesthesia 2002;49:347-352.
ABSTRACT | FULL TEXT  

The Clinical and Biochemical Effects of Propofol Infusion With and Without EDTA for Maintenance Anesthesia in Healthy Children Undergoing Ambulatory Surgery
Cohen et al.
Anesth. Analg. 2001;93:106-111.
ABSTRACT | FULL TEXT  

Candida endophthalmitis: an unusual complication of prolonged intravenous access
Vose et al.
Postgrad. Med. J. 2001;77:119-120.
ABSTRACT | FULL TEXT  

The Growth of Microorganisms in Propofol and Mixtures of Propofol and Lidocaine
Wachowski et al.
Anesth. Analg. 1999;88:209-212.
ABSTRACT | FULL TEXT